Quick Answer
NextCure, Inc. reported Diluted EPS of $19.65 per share (loss) for fiscal year 2025.
NextCure, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$19.65 | +17.7% |
| 2024 | -$23.88 | -961.3% |
| 2023 | -$2.25 | +16.4% |
| 2022 | -$2.69 | -7.2% |
| 2021 | -$2.51 | -88.7% |
| 2020 | -$1.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.22 | +34.9% | +71.5% |
| June 30, 2025 | -$11.29 | -70.8% | -2794.9% |
| March 31, 2025 | -$0.39 | +36.1% | +92.1% |
| September 30, 2024 | -$4.95 | -870.6% | +25.1% |
| June 30, 2024 | -$6.61 | -932.8% | -983.6% |
| March 31, 2024 | -$0.61 | -5.2% | -19.6% |
| September 30, 2023 | -$0.51 | +25.0% | +20.3% |
| June 30, 2023 | -$0.64 | +1.5% | -10.3% |
- NextCure, Inc. showed an increase of +17.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, NextCure, Inc.’s diluted eps has declined by 1377.4% (from $1.33 per share (loss) to $19.65 per share (loss)).
- The most recent figure is from NextCure, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: